Suppr超能文献

针对囊泡单胺转运体2的丁苯那嗪对映体的制备与表征

Preparation and Characterization of Tetrabenazine Enantiomers against Vesicular Monoamine Transporter 2.

作者信息

Yu Qian-Sheng, Luo Weiming, Deschamps Jeffery, Holloway Harold W, Kopajtic Theresa, Katz Jonathan L, Brossi Arnold, Greig Nigel H

机构信息

Drug Design & Development Section, Laboratory of Neurosciences, Intramural Research Program, National Institute on Aging, National Institutes of Health, 251 Bayview Boulevard, Baltimore, Maryland 21224, USA.

出版信息

ACS Med Chem Lett. 2010 Mar 31;1(3):105-109. doi: 10.1021/ml1000189.

Abstract

As a clinical medication for the treatment of hyperkinetic movement disorders, in conditions such as Huntington's disease, tetrabenazine (TBZ) has been always used in its racemic form. To establish whether or not its beneficial therapeutic actions are enantiospecific, a practical total synthetic route was developed to yield each enantiomeric form to allow their chemical and pharmacological characterization. We briefly summarize the total synthesis of TBZ and report a detailed procedure for resolution of TBZ into its enantiomers, (+)-TBZ and (-)-TBZ. This allowed determination of the optical rotation and absolute configurations of each TBZ enantiomer, based on X-ray crystallographic analysis, together with characterization of their inhibitory action at the vesicular monoamine transporter 2, where (+)-TBZ proved three-fold more active than (-)-TBZ.

摘要

作为治疗运动亢进性运动障碍的临床药物,在诸如亨廷顿舞蹈症等病症中,丁苯那嗪(TBZ)一直以来都以消旋体形式使用。为确定其有益的治疗作用是否具有对映体特异性,开发了一种实用的全合成路线来制备每种对映体形式,以便对其进行化学和药理学表征。我们简要总结了TBZ的全合成,并报告了将TBZ拆分为其对映体(+)-TBZ和(-)-TBZ的详细步骤。这使得基于X射线晶体学分析确定了每种TBZ对映体的旋光性和绝对构型,同时还对它们在囊泡单胺转运体2上的抑制作用进行了表征,结果表明(+)-TBZ的活性比(-)-TBZ高三倍。

相似文献

4
Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.
Clin Ther. 2012 Jul;34(7):1487-504. doi: 10.1016/j.clinthera.2012.06.010. Epub 2012 Jun 28.
5
Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders.
Expert Rev Neurother. 2011 Nov;11(11):1509-23. doi: 10.1586/ern.11.149.
6
Tetrabenazine: Spotlight on Drug Review.
Ann Neurosci. 2016 Sep;23(3):176-185. doi: 10.1159/000449184. Epub 2016 Sep 9.
7
Characterization of [11C]tetrabenazine as an in vivo radioligand for the vesicular monoamine transporter.
Nucl Med Biol. 1994 Feb;21(2):151-6. doi: 10.1016/0969-8051(94)90003-5.
8
Management of Huntington's disease: role of tetrabenazine.
Ther Clin Risk Manag. 2011;7:123-9. doi: 10.2147/TCRM.S17152. Epub 2011 Mar 21.
10
Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors.
Eur J Med Chem. 2011 May;46(5):1841-8. doi: 10.1016/j.ejmech.2011.02.046. Epub 2011 Feb 23.

引用本文的文献

2
Application of separation and configuration identification of the four tetrabenazine stereoisomers in determining their pharmacokinetics.
Anal Bioanal Chem. 2025 May;417(11):2253-2266. doi: 10.1007/s00216-025-05813-3. Epub 2025 Mar 8.
5
Enantioselective synthesis of (-)-tetrabenazine continuous crystallization-induced diastereomer transformation.
Chem Sci. 2022 Aug 24;13(36):10765-10772. doi: 10.1039/d2sc01825j. eCollection 2022 Sep 21.
6
Synthesis of Tetrabenazine and Its Derivatives, Pursuing Efficiency and Selectivity.
Molecules. 2020 Mar 5;25(5):1175. doi: 10.3390/molecules25051175.
7
Accelerating the semisynthesis of alkaloid-based drugs through metabolic engineering.
Nat Chem Biol. 2017 Feb 15;13(3):249-258. doi: 10.1038/nchembio.2308.
8
Synthesis of (±)-Tetrabenazine by Visible Light Photoredox Catalysis.
J Org Chem. 2015 Dec 18;80(24):12635-40. doi: 10.1021/acs.joc.5b02199. Epub 2015 Nov 13.
10
Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors.
Eur J Med Chem. 2011 May;46(5):1841-8. doi: 10.1016/j.ejmech.2011.02.046. Epub 2011 Feb 23.

本文引用的文献

1
Tetrabenazine.
Expert Opin Pharmacother. 2009 Dec;10(17):2883-96. doi: 10.1517/14656560903386292.
2
Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2.
J Pharmacol Exp Ther. 2010 Feb;332(2):612-21. doi: 10.1124/jpet.109.160275. Epub 2009 Oct 23.
3
Therapeutic interventions for symptomatic treatment in Huntington's disease.
Cochrane Database Syst Rev. 2009 Jul 8(3):CD006456. doi: 10.1002/14651858.CD006456.pub2.
4
Asymmetric synthesis of tetrabenazine and dihydrotetrabenazine.
J Org Chem. 2009 May 15;74(10):4001-4. doi: 10.1021/jo900480n.
5
The long-term effect of tetrabenazine in the management of Huntington disease.
Clin Neuropharmacol. 2008 Nov-Dec;31(6):313-8. doi: 10.1097/WNF.0b013e318166da60.
6
Vesicular monoamine transporter 2: role as a novel target for drug development.
AAPS J. 2006 Nov 10;8(4):E682-92. doi: 10.1208/aapsj080478.
8
Role of monoamine transporters in mediating psychostimulant effects.
AAPS J. 2005 Dec 20;7(4):E847-51. doi: 10.1208/aapsj070481.
9
Tetrabenazine in the treatment of hyperkinetic movement disorders.
Expert Rev Neurother. 2006 Jan;6(1):7-17. doi: 10.1586/14737175.6.1.7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验